Fig. 3: COH04S1 and sMVA immunogenicity and protective efficacy against mpox in CAST/EiJ mice.
a Study design. CAST/EiJ mice were intramuscularly (IM) vaccinated two times with sMVA at 1 × 106 (n = 9 mice, upward pink triangles. One mouse died post-prime due to vaccine-unrelated causes), 1 × 107 (n = 9 mice, purple squares), and 1 × 108 pfu (n = 9 mice, light blue circles. One mouse died post-boost due to vaccine-unrelated causes), or COH04S1 at 1 × 106 (n = 9 mice, brown diamonds), 1 × 107 (n = 9 mice, downward teal triangles), and 1 × 108 pfu (n = 9 mice, light green hexagons). Unvaccinated mice were used as controls (n = 10 mice [dark green stars]). Serum samples were collected at baseline, day 28 and day 56 for immunological analysis. Mice were intranasally (IN) challenged with mpox clade IIb.1 at day 56 and weight was recorded for 5 days. At day 5, lungs were collected for viral load (VL) assessment. b Neutralizing antibody (NAb) titers. NAb were evaluated at days 28 (post-prime) and 56 (post-boost) using a plaque reduction neutralization test (PRNT). 50% PRNT titers are shown. Dotted line indicates lower detection limit. c Body weight. Shown are body weight changes compared to baseline. d Lung VL. A 50% tissue culture infectious dose (TCID50) assay was used to evaluate lung VL at day 5 post-challenge. Dotted line indicates lower detection limit. Data are presented as box plots extending from 25th to 75th percentiles, with lines indicating medians, and whiskers going from minimum to maximum values. Two-way (b, c) or one-way (d) ANOVA followed by Tukey’s multiple comparison test were used following log transformation. In (d), ****=p  <  0.0001 when comparing each vaccine group to unvaccinated controls.
